AddLife (ALIF) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
21 Oct, 2026Executive summary
Q3 net sales rose 7% to SEK 2,599m, with 4% organic and 3% acquired growth; adjusted EBITA increased 11% to SEK 298m and margin rose to 11.5% from 11.1%.
Profit before tax increased 61%; operating cash flow rose 62% to SEK 236m from SEK 145m, supporting an accelerated acquisition pace.
Financial highlights
Q3 profit after tax increased 56% to SEK 128m; EPS was SEK 1.05 versus SEK 0.66.
Jan–Sep net sales increased 3% to SEK 7,965m; adjusted EBITA rose 6% to SEK 972m and margin reached 12.2% versus 11.9%.
Jan–Sep profit after tax grew 28% to SEK 386m; EPS was SEK 3.15 versus SEK 2.47, while operating cash flow was SEK 505m versus SEK 504m.
Gross margin improved on price management and a higher share of advanced products; elevated operating expenses reflected growth investments and acquisitions.
Outlook and guidance
Management expects to build on positive operating development and favourable market trends in Q4; no numerical full-year forecast was stated.
Acquisition activity is expected to remain high, supported by increased M&A resources and a structured, long-term pipeline.
Three acquisitions during the interim period and one after it are expected to add annual net sales of ~SEK 350m.
September order intake strengthened; management cited healthy UK order books and cautious optimism on UK activity.
Latest events from AddLife
- Q2 and H1 2026 saw higher sales, improved margins, and strong acquisition-driven growth.ALIF
Q2 2026 - High margins, strong organic growth, and acquisitions drive robust performance and outlook.ALIF
Q1 2026 - Profitability and margins improved, debt reduced, and outlook for 2026 is strong.ALIF
Q4 2025 - Profit after tax rose 228% on strong growth, margin gains, and reduced leverage.ALIF
Q3 2025 - Margins and profit surged, led by Labtech, with strong cash flow and a positive M&A outlook.ALIF
Q2 2025 - 3% organic growth, stable margins, and cost savings support a strong Q4 outlook.ALIF
Q3 2024 - Q2 2024 delivered 8% sales and 21% EBITA growth, with improved cash flow and a key acquisition.ALIF
Q2 2024 - Margin and cash flow gains, debt reduction, and Edge Medical deal enable more acquisitions.ALIF
Q1 2025 - Q4 organic growth, margin gains, and cash flow drive higher dividend and positive 2025 outlook.ALIF
Q4 2024